Allergan Plc (AGN)

140.20
NYSE : Health Technology
Prev Close 140.04
Day Low/High 138.76 / 143.86
52 Wk Low/High 125.84 / 197.00
Avg Volume 2.29M
Exchange NYSE
Shares Outstanding 327.80M
Market Cap 45.91B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (2.12%)
Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.

Allergan Must Prove Itself With Signs of More Aggressive Buying

Allergan Must Prove Itself With Signs of More Aggressive Buying

A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

Plus: Jim Cramer interviews Apple CEO Tim Cook about innovation, investments and healthcare technology.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

Allergan To Establish R&D Presence In Cambridge, Massachusetts

Allergan To Establish R&D Presence In Cambridge, Massachusetts

- The facility, located in Kendall Square, is expected to open in 1Q2019 -

ALLERGAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

NEW ORLEANS, Jan. 4, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

Allergan To Report Fourth Quarter And Full Year 2018 Earnings And Host Conference Call And Webcast

Allergan To Report Fourth Quarter And Full Year 2018 Earnings And Host Conference Call And Webcast

DUBLIN, Jan. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it intends to release fourth quarter and full year 2018 financial results on Tuesday, January 29, 2019, prior to the open of U.

Allergan To Present At The 37th Annual J.P. Morgan Healthcare Conference

Allergan To Present At The 37th Annual J.P. Morgan Healthcare Conference

DUBLIN, Dec. 24, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the 37 th Annual J.

Securities Class Action Against Allergan Plc ("AGN") Filed By Block & Leviton LLP; Investors Are Encouraged To Contact The Firm

Securities Class Action Against Allergan Plc ("AGN") Filed By Block & Leviton LLP; Investors Are Encouraged To Contact The Firm

BOSTON, Dec. 21, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

When I looked at the charts this morning I found a stock that could still decline further.

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Buying stocks now means you are in the uncomfortable position of fighting the Fed as it tries to slow the economy.

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Allergan Plc - AGN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Allergan Plc - AGN

NEW YORK, Dec. 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allergan plc ("Allergan" or the "Company") (NYSE: AGN) (ISIN: IE00BY9D5467).

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan's textured breast implants have been linked to a rare form of cancer.

Allergan Suspends Sales And Withdraws Supply Of Textured Breast Implants In European Markets

Allergan Suspends Sales And Withdraws Supply Of Textured Breast Implants In European Markets

- Action Being Taken Following CE Mark Expiration and Compulsory Recall Request by Agence Nationale de Sécurité du Médicament (ANSM) - DUBLIN, Dec.

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?

Aegon Is Driving Financial Performance Through Simplification And Growth

Aegon Is Driving Financial Performance Through Simplification And Growth

At today's Analyst and Investor Conference hosted in New York, CEO Alex Wynaendts and Aegon's US management team will outline how targeted actions to simplify and grow the business are creating significant value for all stakeholders.

I Anticipated Some Volatility Today but I Didn't Expect a Total Collapse

Still, there were some bullish aspects to the action today much as you might think otherwise.

Upcoming Portfolio Review

We'll be out later with key thoughts from our discussion on what direction the portfolio should be taken as we quickly approach a new investment year.

Allergan Makes New Appointments To Finance Leadership Team

Allergan Makes New Appointments To Finance Leadership Team

-- Daphne Karydas named Senior VP, Corporate Financial Planning & Analysis and Strategy --

Allergan To Present At The 2018 Citi Global Healthcare Conference

Allergan To Present At The 2018 Citi Global Healthcare Conference

DUBLIN, Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York...

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For AVYCAZ® (ceftazidime And Avibactam)

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For AVYCAZ® (ceftazidime And Avibactam)

- Application Seeks to Expand the AVYCAZ label to Include Treatment of cUTI and cIAI in Pediatric Patients 3 months of age and older -

Aegon UK Extends Partnership With Atos For Administration Services

Aegon UK Extends Partnership With Atos For Administration Services

Aegon today announces that its subsidiary in the United Kingdom has strengthened its existing partnership with Atos, signing a 15-year contract to service and administer its Existing Business (non-platform customers).

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon's Supervisory Board will propose to the Annual General Meeting of Shareholders in May 2019 to reappoint Alex Wynaendts (58) as Chief Executive Officer of the company, for a four-year term.

Allergan Needs to Rebase on the Charts - Don't Rush It

Allergan Needs to Rebase on the Charts - Don't Rush It

Let's check the charts and technical indicators for some guidance.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

Allergan Shares Fall Despite Q3 Beat, Increased Guidance

The Dublin firm raised its outlook amid a delay in the launch of generic competition to its dry eye medication Restasis.

TheStreet Quant Rating: D+ (Sell)